IRIDEX (NASDAQ:IRIX) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Posted by Jared Coughlin on Jan 5th, 2025

IRIDEX Co. (NASDAQ:IRIX – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.83 and traded as low as $1.71. IRIDEX shares last traded at $1.77, with a volume of 58,312 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on IRIDEX in a report on Saturday. They issued a “hold” rating on the stock.

Read Our Latest Stock Report on IRIDEX

IRIDEX Stock Down 3.3 %

The business’s fifty day simple moving average is $1.68 and its 200 day simple moving average is $1.83. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The stock has a market cap of $29.45 million, a price-to-earnings ratio of -2.64 and a beta of 0.82.

IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The company had revenue of $11.58 million during the quarter. During the same period in the previous year, the company earned ($0.11) EPS.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.